Shopping Cart

Expired activity

Please go to the PowerPak homepage and select a course.

OVERVIEW

Lung cancer is a leading cause of morbidity and one of the most deadly forms of cancer. Divided into 2 classes, non-small-cell and small-cell lung cancer, the disease is now understood to be a group of discrete pathologies with specific characteristics and features. As a result, the therapeutic approach to treating patients with non-small-cell lung cancer (NSCLC) has changed to one focused on histology, molecular selection, and performance status. Tumor screening for a number of prognostic biomarkers in particular has become a critical part of the therapeutic workup and is essential to the optimal management of these patients, enabling clinicians to prescribe newly developed targeted drug therapies to patients whose tumors express the relevant mutations or rearrangements. This enduring module explores the role of these new agents in managing patients with this difficult-to-treat type of cancer, and it will help guide pharmacists, particularly those who work in hospitals and health systems. It will also review the most important biomarkers of genetic aberration and the approved agents to treat patients with those specific tumor types. Emerging therapies and those designed for patients who become resistant to those drugs will also be addressed. Finally, the pharmacist's role in the implementation of personalized cancer treatment will be considered through a review of emerging concerns such as "financial toxicity," drug acquisition, treatment adherence, managing new types of drug-drug interactions, and the role of patient education and counseling.

GOAL

This enduring case activity will enable pharmacists to more accurately identify the role of specific biomarkers in the treatment of patients with NSCLC, assess the efficacy of current and emerging targeted therapies, and formulate individualized treatment plans based on patient-specific factors.

TARGET AUDIENCE

This enduring case activity is designed for oncology pharmacists, health systems pharmacists, and other pharmacists managing patients with NSCLC. No prerequisites required.

LEARNING OBJECTIVES

The University of Tennessee College of Pharmacy takes responsibility for the content, quality, and scientific integrity of this CPE activity. At the conclusion of this activity, the participant should be able to:

• Identify the role of specific biomarkers in the treatment of NSCLC.
• Assess the efficacy and safety of current and emerging targeted therapies.
• Formulate individualized treatment plans for NSCLC based on patient-specific factors.

CREDIT DESIGNATION STATEMENT

The University of Tennessee College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. Successful completion of this knowledge-based program will provide a statement for 0.5 contact hour of credit (0.05 CEU) and will be available at the completion of the activity. Successfully completing the activity and receiving credit includes: 1) attending the session; 2) watching, listening to, and participating in the educational activity; 3) completing the self-assessment instrument  with a score of at least 70%. UAN:  0064-0000-16-231-H01-P. CE credit will be submitted to the NABP CPE Monitor within 30 days.  It is recommended that you check your NABP CPE Monitor e-profile database 30 days after the completion of any CE activity to ensure that your credits are posted.

NABP e-PROFILE ID NUMBER

Pharmacists or pharmacy technicians with questions regarding their NABP e-Profile or CPE Monitor should refer to the FAQ section on the NABP website: https://nabp.pharmacy/cpe-monitor-service/cpe-monitor-faqs/. To receive credit for your participation in this activity, all pharmacists must include their NABP e-Profile ID number, along with their month and date of birth. If incorrect information is provided, this will result in "rejected" status from the CPE Monitor. It is the responsibility of the participant to notify The University of Tennessee (within the 60 day submission timeframe) of their corrected information. Otherwise, the completed CE will not be accepted by the CPE Monitor.

Please allow up to 30 days for your credit to appear on CPE Monitor.

Type of Activity: Knowledge

Published:  December 31, 2016
Expires: December 31, 2017

Media: Internet
Fee Information: There is no fee for this educational activity.

Estimated time to complete activity: 30 minutes

HOW TO EARN CREDIT

Participants must complete the activity as described above in the Credit Designation Statement. To answer the questions, click on your selected choice for each answer then proceed to the next question. We recommend that you print a copy of your answers before you submit them to us. Once completed, click on Submit Post-test at the bottom of the page. Your post-test will automatically be graded. If you successfully complete the post-test (score of 70% or higher), your statement of CE credit will be made available immediately. Click on View Certificate and print the CE statement for your records. If you receive a score lower than 70%, you will receive a message notifying you that you did not pass the post-test. You will have 2 opportunities to pass the post-test.

FULL DISCLOSURE POLICY AFFECTING CPE ACTIVITIES

As an accredited provider by the Accreditation Council for Pharmacy Education (ACPE), it is the policy of The University of Tennessee College of Pharmacy to require the disclosure of the existence of any significant financial interest or any other relationship a faculty member or a sponsor has with the manufacturer(s) of any commercial product(s) discussed in an educational presentation. The Chair/Author reported the following:

PARTICIPATING FACULTY

R. Donald Harvey, PharmD, FCCP, BCOP  (Chair/Author)
Associate Professor, Hematology/Medical Oncology
Director, Phase 1 Clinical Trials Section
Winship Cancer Institute of Emory University
Atlanta, Georgia

Dr Harvey reports receiving grants/research support from Amgen Inc, AstraZeneca, Bristol-Myers Squibb Company, Boston Biomedical, Eli Lilly, Halozyme Inc, Merck & Co Inc, Pfizer Inc, Regeneron Pharmaceuticals Inc, and Syndax; and reports serving as a consultant for Bristol-Myers Squibb Company.

OFF-LABEL PRODUCT DISCUSSION

In accordance with ACPE Criteria for Quality, the audience is advised that discussions in this
CPE activity may include reference(s) to unlabeled, unapproved, or investigational uses of
therapeutic agents or biomedical devices, including, but not limited to, the following:

• Dabrafenib
• Trametinib
• Cabozantinib
• Cabozantinib and crizotinib

DISCLAIMER STATEMENT

The opinions and recommendations expressed by faculty and other experts whose input is included in this activity are their own. This activity is produced for educational purposes only. Use of The University of Tennessee College of Pharmacy name implies review of educational format, design, and approach. Please review the complete prescribing information of specific drugs or combinations of drugs, including indications, contraindications, warnings, and adverse effects, before administering pharmacologic therapy to patients.

GRIEVANCE POLICY

A participant, sponsor, faculty member, or other individual wanting to file a grievance with respect to any aspect of an activity sponsored or cosponsored by The University of Tennessee College of Pharmacy may contact the Associate Dean for Continuing Education in writing at gfarr@utasip.com. The grievance will be reviewed and a response will be returned within 45 days of receiving the written statement. If not satisfied, an appeal to the Dean of the College of Pharmacy can be made for a second level review.

ACTIVITY

The following is an interactive case simulation designed to help you gauge your basic knowledge of the topic and then direct you to areas you may need to focus on. It consists of 3 sections: an unaccredited pre-test, an interactive case study, and a CPE post-test, and evaluation. All 3 sections must be completed to receive CPE credit. A statement of credit will be available online immediately following successful completion of the activity.

REQUIRED COMPUTER HARDWARE/SOFTWARE

Please ensure the computer you plan to use meets the following minimum requirements:

• Operating System: Windows 98 or higher & Macintosh 2.2 or higher
• Internet Browser (Mac &/Windows): Internet Explorer 6.0 or higher, Google Chrome, Safari 5.0.6 or higher, Firefox 3.0.3 or higher & Opera 5 or higher
• Broadband Internet connection: Cable, High-speed DSL & any other medium that is internet accessible.
• Peripherals: Computer speakers or headphones
• Monitor Screen Resolution: 320 x 480 or higher
• Media Viewing Requirements: Adobe Reader, Microsoft Power Point, Flash Player & HTML5

TABLE OF CONTENTS

Preassessment

Targeted Therapies in Non-Small Cell Lung Cancer: An Update for Pharmacists
R. Donald Harvey, PharmD, FCCP, BCOP

Postassessment and Evaluation